Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
暂无分享,去创建一个
Sang-Heon Cho | Joo-Youn Cho | K. Yu | I. Jang | K. Lim | S. Yoon | Tae-Eun Kim | N. Gu | M. Bahng | M. Park
[1] Haiyan Li,et al. Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects , 2012, Clinical Drug Investigation.
[2] V. Basevi. Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.
[3] M. Mcdermott,et al. Erratum to: Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors , 2012, Clinical Pharmacokinetics.
[4] C. Cobelli,et al. Diurnal Pattern to Insulin Secretion and Insulin Action in Healthy Individuals , 2012, Diabetes.
[5] Yan-Ling He. Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin , 2012, Clinical Pharmacokinetics.
[6] Joo-Youn Cho,et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. , 2012, Clinical therapeutics.
[7] A. Scheen. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. , 2012, European journal of internal medicine.
[8] Mi-kyung Kim,et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. , 2012, Life sciences.
[9] A. Scheen. A review of gliptins in 2011 , 2012, Expert opinion on pharmacotherapy.
[10] K. Kazakos,et al. Incretin effect: GLP-1, GIP, DPP4. , 2011, Diabetes research and clinical practice.
[11] A. Corsini,et al. Pharmacology of Dipeptidyl Peptidase-4 Inhibitors , 2011, Drugs.
[12] Ye-Hwang Cheong,et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. , 2011, Bioorganic & medicinal chemistry letters.
[13] K. Toulis,et al. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study. , 2011, Journal of women's health.
[14] M. S. Kirkman,et al. Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.
[15] J. Davidson. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. , 2010, Mayo Clinic proceedings.
[16] J. Gerich. DPP-4 inhibitors: what may be the clinical differentiators? , 2010, Diabetes research and clinical practice.
[17] A. Scheen,et al. Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors , 2010, Diabetes, obesity & metabolism.
[18] D. Drucker,et al. Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits , 2010, Diabetes Care.
[19] A. Mari,et al. Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. , 2009, The Journal of clinical endocrinology and metabolism.
[20] J. Holst,et al. The incretin system and its role in type 2 diabetes mellitus , 2009, Molecular and Cellular Endocrinology.
[21] C. Kahn,et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. , 2005, The Journal of clinical investigation.
[22] R. Pederson,et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats , 2003 .
[23] D. Drucker,et al. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes , 2003, Expert opinion on investigational drugs.
[24] M. Engelgau,et al. A Diabetes Report Card for the United States: Quality of Care in the 1990s , 2002, Annals of Internal Medicine.
[25] A. Astrup,et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity , 2001, International Journal of Obesity.
[26] R N Bergman,et al. Diurnal Variation in Glucose Tolerance: Cyclic Suppression of Insulin Action and Insulin Secretion in Normal-Weight, But Not Obese, Subjects , 1992, Diabetes.
[27] K. Polonsky,et al. Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm. , 1992, The American journal of physiology.
[28] A. Rivellese,et al. Diurnal Variation in Blood Sugar and Serum Insulin in Response to Glucose and/or Glucagon in Healthy Subjects* , 1976, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[29] A. J. Bowen,et al. Diurnal variation in glucose tolerance. , 1967, Archives of internal medicine.
[30] M. Son,et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. , 2011, Diabetes research and clinical practice.
[31] R. Pederson,et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. , 2003, Diabetes.
[32] M. Gutniak. [GLP-1 (7-36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM]. , 1998, Journees annuelles de diabetologie de l'Hotel-Dieu.